Biocon aims for revenue surge with rollout of generic weight-loss drugs
I'm PortAI, I can summarize articles.
Biocon aims for high double-digit revenue growth with the global launch of generic weight-loss drugs, including versions of Novo Nordisk’s Wegovy and liraglutide. The company plans to launch liraglutide in the U.S. in the next financial year and Wegovy in Canada, while being cautious about entering the Indian market due to intense price competition and regulatory hurdles. The global obesity medicines market is projected to reach $150 billion by the early 2030s, with generics expected to be priced significantly lower than original products. Biocon's revenue grew 5.4% in fiscal 2025, with higher quarter-on-quarter growth.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments